Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review

<h3>Background & Aims</h3><p dir="ltr">The BioNTech‐Pfizer vaccine is the only vaccine offered to children among all available vaccines. However, limited evidence is available about the clinical outcomes of COVID‐19 vaccines, especially among children and adolescents....

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Ahmad R. Al‐Qudimat (21348626) (author)
مؤلفون آخرون: Raed M. Al‐Zoubi (21348629) (author), Mai Elaarag (17807390) (author), Abdulqadir J. Nashwan (11659453) (author), Afaf K. Hamze (21348632) (author), Hiba Bawadi (3436379) (author), Aksam Yassin (14779204) (author), Aseel Assim (21348635) (author), Omar M. Aboumarzouk (14779240) (author), Ahmad Zarour (768894) (author), Abdulla A. Al‐Ansari (21348638) (author)
منشور في: 2022
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513548295602176
author Ahmad R. Al‐Qudimat (21348626)
author2 Raed M. Al‐Zoubi (21348629)
Mai Elaarag (17807390)
Abdulqadir J. Nashwan (11659453)
Afaf K. Hamze (21348632)
Hiba Bawadi (3436379)
Aksam Yassin (14779204)
Aseel Assim (21348635)
Omar M. Aboumarzouk (14779240)
Ahmad Zarour (768894)
Abdulla A. Al‐Ansari (21348638)
author2_role author
author
author
author
author
author
author
author
author
author
author_facet Ahmad R. Al‐Qudimat (21348626)
Raed M. Al‐Zoubi (21348629)
Mai Elaarag (17807390)
Abdulqadir J. Nashwan (11659453)
Afaf K. Hamze (21348632)
Hiba Bawadi (3436379)
Aksam Yassin (14779204)
Aseel Assim (21348635)
Omar M. Aboumarzouk (14779240)
Ahmad Zarour (768894)
Abdulla A. Al‐Ansari (21348638)
author_role author
dc.creator.none.fl_str_mv Ahmad R. Al‐Qudimat (21348626)
Raed M. Al‐Zoubi (21348629)
Mai Elaarag (17807390)
Abdulqadir J. Nashwan (11659453)
Afaf K. Hamze (21348632)
Hiba Bawadi (3436379)
Aksam Yassin (14779204)
Aseel Assim (21348635)
Omar M. Aboumarzouk (14779240)
Ahmad Zarour (768894)
Abdulla A. Al‐Ansari (21348638)
dc.date.none.fl_str_mv 2022-07-20T09:00:00Z
dc.identifier.none.fl_str_mv 10.1002/hsr2.740
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Clinical_outcomes_of_Pfizer_BioNTech_COVID_19_vaccine_in_children_and_adolescents_A_systematic_review/29046299
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Cardiovascular medicine and haematology
Immunology
Health sciences
Epidemiology
Public health
adolescents
BNT162b2
children
COVID‐19
Pfizer‐BioNTech
symptoms
vaccine
dc.title.none.fl_str_mv Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Background & Aims</h3><p dir="ltr">The BioNTech‐Pfizer vaccine is the only vaccine offered to children among all available vaccines. However, limited evidence is available about the clinical outcomes of COVID‐19 vaccines, especially among children and adolescents. This review offers a comprehensive and up‐to‐date overview of the BioNTech‐Pfizer vaccine's current information on children and adolescents.</p><h3>Methods</h3><p dir="ltr">The review was conducted following the PRISMA guidelines; a comprehensive search was performed in PubMed, Scopus, MEDLINE, and EMBASE databases for research publications COVID‐19 published between December 2019 and October 2021. All studies reporting on the outcomes of vaccinating children in their respective institutes were included.</p><h3>Results</h3><p dir="ltr">A total of 78 vaccinated children and adolescents from six studies were included. The majority of symptomatic vaccinated pediatrics were males (71%). The mean age was 15.6 years, and the BMI was 24.1. The most common clinical symptoms were found in chest pain (35%), fever (32%), and myalgia (17%). The most common cardiac symptom in the EKG results was ST elevation, and 35% of vaccinated pediatrics had elevated serum troponin. The hospitalization, including ICU admission, was lower than in unvaccinated groups. Statistically significant associations (<i>p</i> ≤ 0.05) were found in two symptoms (fever and headache) between the vaccinated and nonvaccinated pediatric groups.</p><h3>Conclusions</h3><p dir="ltr">Although we found better outcomes in the vaccinated group versus the nonvaccinated pediatric group, more studies are still crucial to further understand the specific etiology underlying postvaccination, particularly myocarditis, psychological impact, and other cardiac clinical symptoms in children and adolescents after receiving the BioNTech‐Pfizer vaccine.</p><h2>Other Information</h2><p dir="ltr">Published in: Health Science Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/hsr2.740" target="_blank">https://dx.doi.org/10.1002/hsr2.740</a></p>
eu_rights_str_mv openAccess
id Manara2_309726574ffc6aa1ffd96c2ef58a555f
identifier_str_mv 10.1002/hsr2.740
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/29046299
publishDate 2022
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic reviewAhmad R. Al‐Qudimat (21348626)Raed M. Al‐Zoubi (21348629)Mai Elaarag (17807390)Abdulqadir J. Nashwan (11659453)Afaf K. Hamze (21348632)Hiba Bawadi (3436379)Aksam Yassin (14779204)Aseel Assim (21348635)Omar M. Aboumarzouk (14779240)Ahmad Zarour (768894)Abdulla A. Al‐Ansari (21348638)Biomedical and clinical sciencesCardiovascular medicine and haematologyImmunologyHealth sciencesEpidemiologyPublic healthadolescentsBNT162b2childrenCOVID‐19Pfizer‐BioNTechsymptomsvaccine<h3>Background & Aims</h3><p dir="ltr">The BioNTech‐Pfizer vaccine is the only vaccine offered to children among all available vaccines. However, limited evidence is available about the clinical outcomes of COVID‐19 vaccines, especially among children and adolescents. This review offers a comprehensive and up‐to‐date overview of the BioNTech‐Pfizer vaccine's current information on children and adolescents.</p><h3>Methods</h3><p dir="ltr">The review was conducted following the PRISMA guidelines; a comprehensive search was performed in PubMed, Scopus, MEDLINE, and EMBASE databases for research publications COVID‐19 published between December 2019 and October 2021. All studies reporting on the outcomes of vaccinating children in their respective institutes were included.</p><h3>Results</h3><p dir="ltr">A total of 78 vaccinated children and adolescents from six studies were included. The majority of symptomatic vaccinated pediatrics were males (71%). The mean age was 15.6 years, and the BMI was 24.1. The most common clinical symptoms were found in chest pain (35%), fever (32%), and myalgia (17%). The most common cardiac symptom in the EKG results was ST elevation, and 35% of vaccinated pediatrics had elevated serum troponin. The hospitalization, including ICU admission, was lower than in unvaccinated groups. Statistically significant associations (<i>p</i> ≤ 0.05) were found in two symptoms (fever and headache) between the vaccinated and nonvaccinated pediatric groups.</p><h3>Conclusions</h3><p dir="ltr">Although we found better outcomes in the vaccinated group versus the nonvaccinated pediatric group, more studies are still crucial to further understand the specific etiology underlying postvaccination, particularly myocarditis, psychological impact, and other cardiac clinical symptoms in children and adolescents after receiving the BioNTech‐Pfizer vaccine.</p><h2>Other Information</h2><p dir="ltr">Published in: Health Science Reports<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/hsr2.740" target="_blank">https://dx.doi.org/10.1002/hsr2.740</a></p>2022-07-20T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/hsr2.740https://figshare.com/articles/journal_contribution/Clinical_outcomes_of_Pfizer_BioNTech_COVID_19_vaccine_in_children_and_adolescents_A_systematic_review/29046299CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/290462992022-07-20T09:00:00Z
spellingShingle Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
Ahmad R. Al‐Qudimat (21348626)
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Immunology
Health sciences
Epidemiology
Public health
adolescents
BNT162b2
children
COVID‐19
Pfizer‐BioNTech
symptoms
vaccine
status_str publishedVersion
title Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
title_full Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
title_fullStr Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
title_full_unstemmed Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
title_short Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
title_sort Clinical outcomes of Pfizer‐BioNTech COVID‐19 vaccine in children and adolescents: A systematic review
topic Biomedical and clinical sciences
Cardiovascular medicine and haematology
Immunology
Health sciences
Epidemiology
Public health
adolescents
BNT162b2
children
COVID‐19
Pfizer‐BioNTech
symptoms
vaccine